Healthcare Industry News:  stroke 

Devices Interventional Cardiology Venture Capital

 News Release - April 19, 2018

Emboline, Inc. Completes Funding Of Over $10 Million

Combination of $3 Million in Equity Financing and Conversion of $7 Million in Convertible Notes will Fund Clinical Trial for the Emboliner™ Embolic Protection Catheter

SANTA CRUZ, Calif., April 19, 2018 -- (Healthcare Sales & Marketing Network) -- Emboline, Inc., an emerging medical device company with a game-changing device for total embolic protection during transcatheter aortic valve replacement (TAVR) procedures, announced today that it has completed a Series B funding round totaling over $10 million. The funding includes $3 million in new equity financing from multiple investors led by SV Tech Ventures and Shangbay Capital, and over $7 million in conversion of previously-issued convertible notes.

"We have been closely monitoring the development of the Emboliner since 2015 and are encouraged by the potential this unique technology has to improve the safety of TAVR and other interventional procedures," said Peng Cheng, Managing Partner at SV Tech Ventures. "This is an exciting time for Emboline as they begin their clinical studies, and we look forward to continuing our work with the Emboline team to bring this technology to patients across the globe."

As part of the financing, ShangBay Capital's William Dai will join SV Tech's Peng Cheng on the Emboline board of directors.

The working capital will be used to fund the SafePass™ Clinical trial for the Emboliner™ Embolic Protection Catheter, the subsequent European CE Mark submission and initial commercial launch.

"The risks of stroke and other neurological damage from TAVR have been getting increased attention in the cardiology community. We recognize that managing these risks will be critical to expanding TAVR into lower risk patient populations," said William Dai, Founding Partner at ShangBay Capital. "The design of the Emboliner device has great advantages over its competitors, and it has the potential to become the leader in the emerging TAVR embolic protection market."

The Emboliner is a truly next-generation approach to reducing the risk of cerebral embolic events or stroke that patients may face following TAVR procedures. The Emboliner design presents significant improvements on first-generation solutions by offering the following:

  • More effective coverage of all cerebral branches with fewer anatomical limitations
  • Full-body embolic protection, capturing both cerebral and non-cerebral debris
  • No additional procedural access required
  • Minimal interference with devices necessary to complete the procedure
  • Outstanding ease-of-use and device control

"As Emboline nears the initiation of our clinical trial to achieve CE Mark approval, this new funding is imperative to securing our place in the embolic protection market," said Scott Russell, Emboline's President & CEO. "We are confident in the superiority of our technology and we are looking forward to offering future TAVR patients a safer procedure."

About Emboline, Inc.

Emboline, Inc., is a privately-held, emerging medical device company that has developed the Emboliner™ Embolic Protection Catheter, a game-changing embolic protection technology for TAVR and other interventional procedures with embolic risks. The novel Emboliner™ device is intended to more reliably protect the cerebral system, while also capturing non-cerebral debris. Emboline's technologies are derived from intellectual property invented by Amir Belson, MD, founder of Neoguide Systems, Vascular Pathways, Zipline Medical, Qool Therapeutics, and others. For more information:

CAUTION: Investigational Device. Limited by United States law to investigational use. Emboline, Emboliner and SafePass are trademarks of Emboline, Inc.

Source: Emboline

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.